Newsroom

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Globalstar, Inc. (NasdaqGS: GSAT) to Amazon.com, Inc. (NasdaqGS: AMZN). Under the terms of the proposed transaction, shareholders of Globalstar will receive $90.00 in cash or 0.3210 shares of Amazon common stock (with a value capped at $90.00 per share), for each share of Globalstar that they o...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of FatPipe Inc. (NASDAQ: FATN) resulting from allegations that FatPipe may have issued materially misleading business information to the investing public. So what: If you purchased FatPipe securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Ro...

TORONTO & BERLIN--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”) and Sanity Group GmbH (“Sanity” or “Sanity Group”) jointly announced the successful closing of Organigram’s previously announced acquisition (the “Acquisition”) of Sanity Group, pursuant to the terms of a share purchase agreement dated February 18, 2026 (the “Share Purchase Agreement”). In connection with closing of the Acquisition, a wholly owned subsidiary of the Company acquire...

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Avanos Medical, Inc. (NYSE: AVNS) to affiliates of American Industrial Partners. Under the terms of the proposed transaction, shareholders of Avanos will receive $25.00 in cash for each share of Avanos that they own. KSF is seeking to determine whether this consideration and the process that le...

PARIS--(BUSINESS WIRE)--Regulatory News: Getlink SE (Paris: GET) Presenter / Corporate Name : Getlink SE - Société Européenne, RCS Paris 483 385 142 37-39 rue de la Bienfaisance, 75008 Paris Date Number of ordinary shares in issue (1) Number of voting rights Theoretical (2) (3) Exercisable (4) 13 April 2026 550,000,000 642,638,842 634,673,889 * * * * (1) The share capital is divided into 550,000,000 ordinary shares of a nominal value of €0.40. (2) In accordance with Article 223-11 of the AMF Ge...

CAMPBELL, Calif.--(BUSINESS WIRE)--Mirantis, delivering Kubernetes-native infrastructure for AI, today announced the company is enabling enterprises and neocloud providers to deploy production-ready AI platforms in minutes, not weeks which is achieved by automated deployment and lifecycle management of NVIDIA Run:ai through the Mirantis k0rdent AI platform. The integration closes the gap between GPU infrastructure provisioning and a fully operational AI factory. As organizations race to build p...

LOS ANGELES--(BUSINESS WIRE)--Puptqe expands to Texas with its first Woodlands/Spring location, bringing dog-focused retail, events, and its PupPass+ membership to Houston....

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et du système nerveux central, annonce avoir déposé le 14 avril 2026 son document d’enregistrement universel (URD) 2025 en langue anglaise auprès de l’Autorité des Marchés Financiers (AMF) sous le numéro D.26-0251. Le doc...

BOCA RATON, Fla.--(BUSINESS WIRE)--SurGenTec, LLC, a leader in innovative spine and orthopedic technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its TiLink™ Navigation Instruments for use with the TiLink™ SI Joint Fusion System in sacroiliac joint procedures. The system is engineered for compatibility with Medtronic’s StealthStation™ navigation platform, enabling enhanced precision during minimally invasive SI joint fusion surgeries....

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that its 2025 Universal Registration Document (URD) in English was filed with the French market authority (Autorités des Marchés Financiers, or AMF) on April 14, 2026, under the reference D.26-0251. The Univ...